Rights and permissions
About this article
Cite this article
The long-acting injection formulation of risperidone [Risperdal Consta] will be fully funded for patients with psychotic disorders in New Zealand (NZ) from 1 October this year. Pharmacoecon. Outcomes News 487, 14 (2005). https://doi.org/10.2165/00151234-200504870-00040
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200504870-00040